June 12 – 17, 2022
Vero cells are nowadays widely used in the production of vaccines. However, they are anchorage dependent, which greatly complicates upstream processing and process scale-up. Moreover, there is a recognized need to reduce the costs of vaccine manufacturing to develop vaccines affordable worldwide. The use of cell lines adapted to suspension growth contributes to reach this objective. We had previously adapted Vero cells to suspension growth for rabies virus (strain LP2061) production in different serum free media (Rourou et al. 2019).
In this work, we describe the use of a chemically defined medium (CDM) provided by Xell AG to assess the growth of suspension adapted Vero cells, VeroS, and the production of both rabies and Bluetongue Serotype 1 (BTV-1) viruses.
The viruses were first adapted to VeroS grown on CDM by successive passages. Then, kinetics of cell growth and virus production were studied in shake flask cultures.
Please click Download on the upper right corner to see the full abstract.
Samia Rourou and Ikram Ben Marzouk, "Towards a virus production platform based on VeroS cells grown on chemically defined media" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/67